Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials-Reference-Cited by-同舟云学术

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

Published:2019-02-12 Issue:7 Volume:139 Page:863-873
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Fanaroff Alexander C.¹²,Clare Robert²,Pieper Karen S.²,Mahaffey Kenneth W.³,Melloni Chiara¹²,Green Jennifer B.²⁴,Alexander John H.¹²,Jones W. Schuyler¹²,Harrison Robert W.¹²,Mehta Rajendra H.²,Povsic Thomas J.¹²,Moreira Humberto G.⁵,Al-Khatib Sana M.¹²,Roe Matthew T.¹²,Kong David F.¹²,Mathews Robin¹²,Tricoci Pierluigi⁶,Holman Rury R.⁷,Wallentin Lars⁸,Held Claes⁸,Califf Robert M.¹²⁹,Alexander Karen P.¹²,Lopes Renato D.¹²

Affiliation:

1. Division of Cardiology (A.C.F., C.M., J.H.A., W.S.J., R.W.H., T.J.P., S.M.A-K., M.T.R., D.F.K., R.M., R.M.C., K.P.A., R.D.L.), Duke University School of Medicine, Durham, NC.

2. Duke Clinical Research Institute (A.C.F. R.C., K.S.P., C.M., J.B.G., J.H.A., W.S.J., R.W.H., R.H.M., T.J.P., S.M.A-K., M.T.R., D.F.K., R.M., R.M.C., K.P.A., R.D.L.), Duke University School of Medicine, Durham, NC.

3. Stanford Center for Clinical Research, Stanford University School of Medicine, CA (K.W.M.).

4. Division of Endocrinology (J.B.G.), Duke University School of Medicine, Durham, NC.

5. Heart Institute (InCor), University of São Paulo Medical School, Brazil (H.G.M.).

6. CSL Behring, King of Prussia, PA, (P.T.).

7. Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, United Kingdom (R.R.H).

8. Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Institute, Uppsala University, Sweden (L.W., C.H.).

9. Verily Life Sciences, South San Francisco, CA (R.M.C.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference31 articles.

1. Hicks KA Hung H Mahaffey KW Mehran R Nissen SE Stockbridge NL Targum SL Temple R. Standardized definitions for cardiovascular and stroke end point events in clinical trials. Clinical Data Interchange Standards Consortium. https://www.cdisc.org/system/files/all/standard/Draft%20Definitions%20for%20CDISC%20August%2020%2C%202014.pdf. August 20 2014. Accessed October 2 2018.

2. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

3. FDA Briefing Document: Endocrine and Metabolic Drug Advisory Committee Meeting: June 28 2016. https://www.fda.gov/downloads/AdvisoryCommittees/UCM508422.pdf. 2016. Accessed October 2 2018.

4. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

5. Effect of valsartan on the incidence of diabetes and cardiovascular events.;NAVIGATOR Study Group;N Engl J Med,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the COVID‐19 Pandemic on Conduct and Results of CLEAR Outcomes Trial;Clinical Cardiology;2024-07-30

2. Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL;American Heart Journal;2024-05

3. LPS adsorption and inflammation alleviation by polymyxin B-modified liposomes for atherosclerosis treatment;Acta Pharmaceutica Sinica B;2023-09

4. Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation;Journal of the American Heart Association;2023-07-18

5. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis;European Heart Journal - Cardiovascular Pharmacotherapy;2023-01-13